Biofrontera AG: Biofrontera and GME enter into a cooperation to promote the MultiLite® daylight lamp for PDT treatment

Leverkusen/Erlangen, Germany (pta018/19.02.2024/11:45 UTC+1)

Biofrontera AG (FSE: B8F), an international biopharmaceutical company, and GME - German Medical Engineering GmbH announce that Biofrontera AG's subsidiary Biofrontera Pharma GmbH has entered into a strategic collaboration with German Medical Engineering GmbH (GME) to strengthen the commercialization of the MultiLite® daylight lamp for the photodynamic therapy (PDT) of actinic keratoses (AK) in Germany and the UK.

Biofrontera's PDT product Ameluz® has a wide range of approvals, from conventional PDT to daylight PDT. With the recent label extension of Ameluz® for the use of artificial daylight, a further treatment option is now available that allows PDT to be tailored even more individually to the needs of patients and physicians. Treatment with artificial daylight, e.g. with the MultiLite®, provides many advantages: it is as almost painless as natural daylight PDT, but is not dependent on the weather and takes place entirely under medical supervision.

The partnership between Biofrontera and GME aims to significantly increase the availability of PDT for the treatment of actinic keratoses in dermatology hospital units and clinics, so that this effective therapy will gain significant presence in the market in the coming years.

Dr. Stefan Schulze, Managing Director of GME, is delighted about the collaboration: "As a German medtech company, the partnership with Biofrontera as provider of the PDT drug Ameluz® results in unique advantages. Our MultiLite® PDT system becomes even more flexible in combination with Ameluz®. The MultiLite® emits light in three different colors, each of which is generated by special LEDs. This concept allows us to use PDT in a variety of ways in a single device requiring little floor space."

"With the treatment option of artificial daylight PDT, we can respond even better to the needs of patients and medical practices, as it is a low-pain treatment option that is also independent of the weather and is carried out entirely under medical supervision. In addition, a flexible treatment protocol with Ameluz® allows the duration of incubation and light exposure to be adapted to a reasonable extent to practice processes. Through the cooperation with GME, we hope to expand a network of medical practices in which patients can now be offered the various options of PDT with Ameluz® all throughout the entire year," adds Dr. Axel Drews, Vice President Global Marketing & Sales at Biofrontera.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor Relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	ir@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE0006046113 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate